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Abstract
Aims To evaluate early outcomes of patients with hepa-
tocellular carcinoma (HCC) treated with a novel radio-
paque bead, the 75–150 lm DC Bead LUMITM
(Biocompatibles UK Ltd).
Materials and Methods This was a retrospective review of
the first 40 consecutive patients at a UK tertiary hepato-
biliary centre, treated for HCC with TACE using radio-
paque beads, between May 2017 and March 2019. Infor-
mation regarding complications, mortality, lesion response
and subsequent ablation procedures was collected from
electronic records and case notes. Intra- and post-operative
imaging was reviewed for visibility of the embolised
territory.
Results Fifty-five TACE procedures were performed in 40
patients, with a median age of 70 years (range 28–88) and
median lesion size of 3.8 cm (range 1.5–7.8). The median
follow-up period was 30 weeks (range 6–101). Mean post-
procedure hospital stay was 1.2 days. Complications of
CIRSE Grade II or above occurred after 4/55 procedures
(7.3%). Mortality at 30 days was zero. Objective response
rates (mRECIST) at 1, 3 and 6 months were 32/35 (91.4%),
21/24 (87.5%) and 12/15 (80%), respectively. Complete
response rates at 1, 3 and 6 months were 16/35 (45.7%),
12/24 (50%) and 9/15 (60%). The embolised territory was
visible on intra-operative and follow-up CT imaging in all
patients. The radiopaque beads were used as a fiducial
marker to guide ablation in 5/40 patients (12.5%).
Conclusion TACE with radiopaque beads shows promis-
ing tolerability and efficacy. The radiopaque beads ensure
visualisation of the embolised lesion on intra- and post-
operative imaging and, in selected cases, can act as a
marker for CT-guided ablation.
Keywords TACE  Trans-arterial
chemoembolisation  HCC  Hepatocellular
carcinoma  LUMI
Introduction
Trans-arterial chemo-embolisation (TACE) is an estab-
lished treatment option for intermediate-stage hepatocel-
lular carcinoma (HCC) [1–3]. Two dominant approaches
have been proposed, conventional TACE (cTACE) and
drug-eluting bead TACE (DEB-TACE).
While neither has been shown to confer an overall sur-
vival advantage, DEB-TACE has the advantage of lower
concentrations of chemotherapeutic agent reaching the
systemic circulation, with fewer attendant side effects;
however, some operators prefer cTACE due to the superior
visibility on intra-operative imaging of ethiodised oil
compared to the mixture of beads and contrast medium
used in DEB-TACE [4–6]. Following cTACE, lipiodol
may be retained by tumour cells for several months, and
therefore the embolised lesion may be visualised on post-
operative CT [7]; however, following DEB-TACE the
contrast agent dissipates, meaning the embolised territory
cannot be directly visualised.
DC Bead LUMITM (Biocompatibles UK Ltd, UK) is a
bead with iodine incorporated into its chemical structure,
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ensuring that it is permanently radiopaque [8]. This
potentially combines the advantages of DEB-TACE, with
low systemic drug absorption, and cTACE, with good
visualisation on post-operative imaging. Despite this the-
oretically promising concept, little is known about the
bead’s safety profile and efficacy [9–11]. This study eval-
uates early outcomes in the first cohort of patients treated
with radiopaque beads at our institution.
Materials and Methods
Patient Cohort
We conducted a retrospective review of the first 40 con-
secutive patients who underwent TACE for HCC with DC
Bead LUMITM at our institution, a tertiary hepato-biliary
referral centre in the UK. The study period was May 2017–
March 2019. Patient demographics, underlying aetiology,
BCLC tumour stage and liver function, were obtained from
the clinical notes, electronic patient record and picture
archiving and communication system (PACS). In all cases,
HCC was diagnosed according to current European Asso-
ciation for Study of Liver guidelines [3] and all patients
were deemed suitable for TACE by a multi-disciplinary
tumour board. All procedures were performed in accor-
dance with the ethical standards of the institutional
research committee and with the 1964 Helsinki Declaration
and its later amendments [12].
Complications were recorded and classified according to
the CIRSE system [13]. Follow-up imaging was reviewed
for evidence of response in the treated lesions, according to
mRECIST [14]. For patients who underwent more than one
TACE, the follow-up period was deemed to start on the
date of the first treatment. Patient survival was documented
until April 30, 2019.
Follow-Up Imaging Protocol
Standard imaging follow-up was quadruple-phase CT (pre-
contrast, arterial, portal venous and delayed venous phases)
at 1- and 3-month post-TACE, and then at 3-month inter-
vals thereafter. MRI was reserved mainly for lesions with
equivocal response on CT, given relatively limited local
availability of MRI.
Outcome Measures
Primary outcome measures were TACE-related complica-
tions, lesion response at 1, 3 and 6 months after the initial
procedure and 30-day mortality.
Two radiologists reviewed imaging for all patients,
including intra-operative fluoroscopy and (if available)
cone-beam CT (CBCT) from each patient’s first TACE
procedure with radiopaque beads, and follow-up pre-con-
trast CT imaging at 1 and 12 months, to determine whether
the embolised territory (the HCC itself and/or the peri-
tumoral vessels) could be clearly identified.
We recorded all patients who subsequently underwent
ablation procedures, noting whether the radiopaque beads
were used as a fiducial marker to aid placement of the
ablation needle under CT guidance.
Exclusion Criteria
Four patients who underwent additional treatments for
HCC in the first month following TACE (3 underwent
thermal ablation and 1 liver transplantation) were excluded
from analysis of treatment response.
DC Bead LUMITM Technical Considerations
The DC Bead LUMITM is available in two sizes—
70–150 lm and 100–300 lm. The core chemical structure
is the same as the DC BeadTM, a polyvinyl alcohol-2-
acrylamido-2-methylpropane sulphonic acid hydrogel
bead. To create the DC Bead LUMITM, an iodine-con-
taining moiety—2,3,5-triiodobenzaldehyde—is added to
the PVA backbone.
As well as rendering it radiopaque, incorporation of this
moiety affects the bead’s physical properties in two addi-
tional ways: its density (1.3 g/cm3) is 30% greater and its
compressibility is two orders of magnitude lower compared
to the DC BeadTM. The increased density results in more
rapid sedimentation; therefore, it is recommended that DC
Bead LUMITM is mixed with a high-viscosity contrast
agent to maintain a workable suspension and micro-
catheters flushed with contrast agent rather than saline to
ensure bead clearance [8].
Unlike the DC BeadTM, which shrinks between 20 and
30% when loaded with doxorubicin, the DC Bead LUMITM
remains the same size following drug loading. Its drug
loading and elution kinetics are similar to the DC BeadTM
[8].
Doxorubicin-Loading and Dosage Protocol
Beads were loaded with doxorubicin by in-house pharmacy
staff according to protocols developed in conjunction with
the manufacturers. Dosage was in line with published
recommendations, i.e. planned doses of up to 75 mg dox-
orubicin loaded onto one 2-ml vial of beads if the disease
was within the Milan criteria for liver transplantation, or up
to 150 mg doxorubicin loaded onto two vials of beads for
more advanced disease [15].
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Procedure Details
All patients received broad-spectrum antibiotic prophylaxis
for 3 days, starting on the day of the procedure.
All procedures were carried out using common femoral
artery access. In all cases, digital subtraction angiography
and CBCT were used to map the tumour vessels and allow
selective or super-selective embolisation, aiming for an
endpoint of pre-stasis. In 25/55 procedures, post-emboli-
sation CBCT was performed to evaluate completeness of
tumour coverage; this was dependent on factors including
radiation dose, lesion characteristics and operator
preference.
In 53/55 cases, a 2.7Fr progreat microcatheter (Terumo
Corporation, Japan) was used; a steerable SwiftNINJATM
microcatheter (Merit Medical, USA) with a 2.4Fr tip was
used in one patient with tortuous anatomy, and a 2.0Fr
progreat microcatheter was used in one case with small
tumour vessels.
The smaller bead size (75–150 lm) was used in all
cases. Beads were mixed with high osmolarity contrast
agent, typically omnipaque 350 mg/ml (GE Healthcare,
USA), at a ratio of 2-ml beads (i.e. one vial) to 18 ml
contrast agent. Just prior to administration, the mixture was
agitated between two syringes to maintain a uniform sus-
pension and injected using controlled pulses from a 2-ml
syringe at an approximate rate of 1 ml/min under direct
fluoroscopic screening.
Results
Patient Cohort
Fifty-five TACE procedures with DC Bead LUMITM were
carried out in 40 patients (37 men and 3 women), a mean of
1.4 procedures per patient. The median age was 70 years
(mean 68.6, range 28–88). The median lesion size was
3.8 cm (mean 4.0, range 1.5–7.8). Disease characteristics
are summarised in Table 1.
Adverse Events and Complications
All 55 procedures were completed as planned with no
intra-operative complications. Thirty-day mortality was
zero. Minor complications requiring no additional therapy
or deviation from the standard post-operative course (i.e.
CIRSE Classification Grade 1) [13] were recorded after
eight procedures—six patients reported post-procedure
discomfort and two reported minor groin bruising.
Post-operative complications which required additional
treatment or further hospital stay (i.e. CIRSE Grade 2 or
above) occurred after four procedures, as summarised in
Table 2.
The first three documented complications were in
patients who had relatively high-volume disease (le-
sions C 4.5 cm). The fourth—a liver abscess in the
embolised liver segment—occurred in a patient who also
had obstructing common bile duct (CBD) calculi with
intrahepatic duct dilatation. This was not detected on the
pre-TACE imaging, blood tests or clinical examination.
Lesion Response Rates
Lesion response rates are summarised in Table 3. After
exclusion criteria were applied, 1-month follow-up was
available for 35 patients, 3-month follow-up for 24 patients
and 6-month follow-up for 15 patients. Objective response
Table 1 Basic disease characteristics
Aetiology of liver disease
Non-alcoholic fatty liver (NAFLD) 14 (35%)
Alcoholic liver disease (ALD) 9 (22.5%)
Mixed 3 (7.5%)
Hepatitis C 4 (10%)
Other/unknown 8 (20%)
No background liver disease 2 (5%)
Cirrhosis
Cirrhotic 28 (70%)
Non-cirrhotic 12 (30%)
Histological diagnosis
Well differentiated HCC 10 (25%)
Moderately differentiated HCC 10 (25%)
Poorly differentiated HCC 3 (7.5%)
No histology (radiological diagnosis) 17 (42.5%)
Number of lesions
1 lesion 31 (77.5%)
2 lesions 7 (17.5%)
3 lesions 2 (5%)
Size of target lesion (or largest lesion if multiple)
B 2 cm 3 (7.5%)
2.1–3 cm 10 (25%)
3.1–4 cm 11 (27.5%)
4.1–5 cm 7 (17.5%)
[ 5 cm 9 (22.5%)
BCLC stage
Stage A 17 (42.5%)
Stage B 23 (57.5%)
Child–Pugh score
A 39 (97.5%)
B 1 (2.5%)
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was calculated by adding complete response and partial
response.
Survival
38/40 patients (95%) remain alive, with a median follow-
up period of 6 months (range 1–23). 2/40 patients (5%)
have died during the follow-up period. The first (male,
71 years) had an initial TACE procedure with radiopaque
beads for two right-lobe HCCs (3.8 cm and 4.0 cm), with
complete response in both lesions on imaging up to
6 months. The CT at 9 months showed recurrence in one of
the lesions, which was targeted with a second TACE pro-
cedure at 10 months, achieving a partial response at
11 months. Subsequent imaging showed progressive dis-
ease. He was deemed unsuitable for further TACE or
medical therapy. He received supportive care and died
10 months later, 21 months after the first TACE.
The second death occurred in a 63-year-old man treated
for a 5.0-cm moderately differentiated HCC, with a back-
ground of Child–Pugh A alcohol-induced cirrhosis. His
1-month follow-up scan post-TACE showed stable disease;
at 3 months, there was recurrence in the treated lesion and
new lesions elsewhere in the liver. He subsequently
developed ascites and encephalopathy and died 5 months
after the TACE procedure.
Imaging
Both radiologists reviewing the imaging agreed that in all
40 patients, the embolised territory was clearly visible on
intra-operative fluoroscopy. Post-embolisation CBCT was
performed in 21/40 patients (52.5%) at their first TACE
procedure, and in all cases the embolised territory was
clearly visible. In 39/39 patients with 1-month follow-up
CT imaging available, the embolised territory was clearly
visible on the unenhanced scan, regardless of whether or
not there had been an intervening ablation procedure. In
10/10 patients with 12-month follow-up CT imaging
available, the embolised territory remained clearly visible
on the unenhanced scan.
MRI was used in addition to CT for follow-up imaging
in 10/40 patients (25%).
Ablation
In the follow-up period, 6/40 patients (15%) subsequently
underwent microwave ablation of lesions initially treated
by TACE. This included four patients with HCC under
3 cm in diameter, who underwent ablation within 6 weeks
of TACE as a pre-planned second stage of treatment. One
patient had a 3-month scan showing partial response fol-
lowing TACE of a 3-cm lesion and had an ablation tar-
geting the area of residual enhancement. One patient
underwent CT-guided ablation of a small nodule of local
Table 2 Summary of post-procedure complications requiring additional treatment or hospital stay
Complication Treatment required CIRSE
classification
[14]
1 Post-embolisation syndrome
(fever)
Inpatient stay extended by 72 h for monitoring Grade 3
2 Post-embolisation syndrome
(malaise, fever)
Attended hospital for unplanned clinical review. Discharged with advice Grade 2
3 Post-embolisation syndrome
(pain, fever)
48-h admission for symptomatic treatment Grade 3
4 Liver abscess Re-admitted day 13 with newly diagnosed CBD stones, and liver abscess in the segment
treated by TACE, requiring IV antibiotics and percutaneous drainage. No permanent
sequelae
Grade 3
Table 3 Lesion response on
early post-treatment imaging
according to mRECIST
1 month 3 months 6 months
Number of patients with data available 35 24 15
Complete response 16(45.7%) 12 (50%) 9 (60%)
Partial response 16 (45.7%) 9 (37.5%) 3 (20%)
Objective response 32(91.4%) 21 (87.5%) 12 (80%)
Stable disease 2 (5.7%) 1 (4.2%) 0
Progressive disease 1 (2.9%) 2 (8.3%) 3 (20%)
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recurrence 18 months after the initial TACE (discussed
below).
In five of six patients who underwent ablation, tumour
staining with radiopaque beads was used as a fiducial
marker to assist needle placement under CT guidance. In
the other patient, the lesion was targeted with ultrasound.
All patients treated with ablation showed no evidence of
local recurrence in the follow-up period.
Discussion
Safety
A previous study involving over 400 DEB-TACE treat-
ments suggests that some degree of post-embolisation
syndrome is a near-universal feature, with more severe
post-embolisation symptoms reported in 27.1% of patients
[16]. While comparison with our results is challenging
given the differences in data collection, we observed post-
embolisation syndrome requiring further hospital stay or
medical assessment after only 3/55 procedures (5.5%).
Regarding the other significant complication we
observed, the obstructing CBD calculi are thought to have
played a major role in the development of the liver abscess.
Had the biliary obstruction been appreciable on pre-oper-
ative evaluation, TACE would have been postponed until
after duct clearance.
Efficacy
Given this study’s retrospective design, absence of a con-
trol group and relatively short follow-up periods for many
of the patients, analysis of tumour response is limited. Any
comparison of outcomes with other studies should be
approached with caution given potential differences in
study design, patient selection and TACE technique.
However, early response rates in our cohort fall within the
expected range, given previously reported peak response
rates following DEB-TACE of between 44 and 99.5%
[5, 16, 17].
Intra-operative Imaging
Our findings demonstrate that the radiopaque beads allow
the embolised territory to be clearly seen intra-operatively,
both on fluoroscopy and CBCT, an example is shown in
Fig. 1. Good intra-operative visualisation means that non-
target embolisation can be recognised, potentially allowing
catheter repositioning to minimise the associated risks.
Follow-Up Imaging
We have demonstrated that the embolised territory fol-
lowing treatment with radiopaque beads remains visible on
follow-up CT imaging (Fig. 2). Consequently, radiologists
involved in reporting follow-up imaging must be made
aware of the differences in expected appearances following
TACE with radiopaque beads, in order to reduce the
potential for misinterpretation. For example, hyper-density
in the embolised territory on pre-contrast imaging should
be recognised as staining by radiopaque beads and not
mistaken for post-treatment calcification. Contrast-
Fig. 1 Intra-operative imaging. a a fluoroscopic image and b a
coronal image from cone-beam CT, both taken at the end of the
procedure, demonstrating tumour staining with a combination of
radiopaque beads and trapped contrast medium
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enhanced MRI, used in one quarter of our cohort, may be
helpful if follow-up CT is equivocal.
Tumour Marking for Ablation
We have demonstrated that the beads’ visibility on follow-
up CT imaging can mark lesions for ablation under CT
guidance. Given that the beads remain visible after abla-
tion, post-treatment margins can also be assessed on sub-
sequent CT imaging.
One patient in our cohort (Fig. 3) illustrates the value of
radiopaque beads with respect to subsequent ablation. A
74-year-old male with a 3.7-cm segment 7 HCC, consid-
ered too big for primary ablation [3], underwent TACE
with radiopaque beads. Follow-up imaging demonstrated
complete response, with a reduction in lesion size to
12 mm, until a CT at 18 months showed a small
(\ 10 mm) area of recurrence at the lesion’s inferior
Fig. 2 Post-operative imaging, noncontrast (Fig. 2a) and arterial
phase (Fig. 2b) coronal images from the 1-month follow-up CT from
the same patient as Fig. 1, demonstrating persistent tumour staining
with radiopaque beads. There was no postcontrast enhancement,
indicating a complete response according to mRECIST
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aspect. With the disease now effectively down-staged fol-
lowing TACE, microwave ablation was performed with the
radiopaque beads aiding needle placement under CT
guidance. Follow-up CT one month later showed satisfac-
tory ablation margins.
As well as ablation of recurrent or down-staged disease
following TACE, there is increasing interest in the role of
combining TACE and ablation as a primary treatment
strategy, given that tumour necrosis induced by prior
chemo-embolisation may result in better conduction of
thermal energy and therefore more effective ablation
[18, 19]. This approach was employed in four patients in
our cohort, with radiopaque beads facilitating CT-guided
ablation in three cases.
Limitations
The retrospective design of the study, with no control
group, means that the results do not reliably demonstrate
the relative performance of radiopaque beads compared to
more established products. Furthermore, it is problematic
to compare our results with those of other studies given
differences in patient selection, disease characteristics and
embolisation strategy.
While radiopaque beads offer opportunities to explore
correlations between bead distribution and clinical out-
comes, which may help guide future developments in
TACE techniques, such analysis is beyond the scope of this
study in view of the small number of patients and variable
follow-up period.
Given that data relating to complications were collected
retrospectively from clinical records, we are likely to have
under-estimated post-embolisation symptoms compared to
others who conducted questionnaires for all patients [16].
Conclusion
While the results of other studies evaluating TACE with
DC Bead LUMITM are awaited [20], we have demonstrated
promising early clinical outcomes of this radiopaque bead.
It ensures good intra- and post-operative visualisation and
can facilitate subsequent CT-guided ablation in appropriate
cases, either as a planned primary treatment strategy or for
recurrent disease. Further evaluation will be required to
optimise patient selection and establish conclusively the
efficacy and safety of this new embolic agent.
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